

Announcement No. 15/2012
To NASDAQ OMX Copenhagen

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

6 December 2012

Exiqon A/S announces financial calendar for 2013

Below are the expected dates for Exiqon A/S' annual general meeting and financial reporting in 2013.

Financial calendar

Announcement of full-year results 2012:	6 February 2013
Deadline for shareholders' proposal to the annual general meeting:	21 February 2013
The annual general meeting is scheduled to be held on:	4 April 2013
Interim report for the period 1 January 2012 to 31 March 2013:	6 May 2013
Interim report for the period 1 January 2012 to 30 June 2013:	16 August 2013
Interim report for the period 1 January 2012 to 30 September 2013:	29 October 2013

Additional information

Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)

About Exiqon

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of miRNA research products for miRNA analysis in cells. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on miRNA as biological markers. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.